Alzheimer's Disease and Immunotherapy

被引：0
作者：
Madeo, Jennifer [1 ]
Frieri, Marianne [1 ]
机构：
[1] Nassau Univ, Med Ctr, Dept Med, E Meadow, NY 11554 USA
来源：
AGING AND DISEASE | 2013年 / 4卷 / 04期
关键词：
Alzheimer's disease; immunotherapy; immunosenescence; vaccination; monoclonal antibodies; AMYLOID-BETA IMMUNOTHERAPY; CENTRAL-NERVOUS-SYSTEM; A-BETA; COGNITIVE IMPAIRMENT; MOUSE MODEL; PASSIVE IMMUNOTHERAPY; TRANSGENIC MOUSE; CLINICAL-TRIALS; DOUBLE-BLIND; MEMORY LOSS;
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
Alzheimer's disease (AD) is a growing health care epidemic. It is the most common cause of dementia and its incidence is rising. Age, which influences the oxidative and inflammatory states of the brain, is the most important risk factor. Currently there is no disease modifying treatments available for this irreversible, progressive debilitating disease. Immunotherapy represents an emerging, potentially disease modifying strategy aimed at reducing the pathological lesions of AD and facilitating cognitive improvement. Many clinical trials are currently underway. This literature review highlights current knowledge regarding the physiology of aging and how it relates to the pathogenesis of AD. In addition, immunotherapy is discussed in the context of its mechanism, current studies and future goals.
引用
收藏
页码：210 / 220
页数：11
相关论文
共 89 条
[41]   Phospholipids and Alzheimer's Disease: Alterations, Mechanisms and Potential Biomarkers [J].
Kosicek, Marko ;
Hecimovic, Silva .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (01) :1310-1322
[42]  
Kotilinek LA, 2002, J NEUROSCI, V22, P6331
[43]   Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease: A Phase I, Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Study [J].
Landen, Jaren W. ;
Zhao, Qinying ;
Cohen, Sharon ;
Borrie, Michael ;
Woodward, Michael ;
Billing, Clare B., Jr. ;
Bales, Kelly ;
Alvey, Christine ;
McCush, Fred ;
Yang, Jerry ;
Kupiec, James W. ;
Bednar, Martin M. .
CLINICAL NEUROPHARMACOLOGY, 2013, 36 (01) :14-23
[44]   Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: Lessons from mice, monkeys, and humans [J].
Lemere, CA ;
Maier, M ;
Jiang, LY ;
Peng, Y ;
Seabrook, TJ .
REJUVENATION RESEARCH, 2006, 9 (01) :77-84
[45]   Alzheimer's disease Aβ vaccine reduces central nervous system Aβ levels in a non-human primate, the Caribbean Vervet [J].
Lemere, CA ;
Beierschmitt, A ;
Iglesias, M ;
Spooner, ET ;
Bloom, JK ;
Leverone, JF ;
Zheng, JB ;
Seabrook, TJ ;
Louard, D ;
Li, D ;
Selkoe, DJ ;
Palmour, RM ;
Ervin, FR .
AMERICAN JOURNAL OF PATHOLOGY, 2004, 165 (01) :283-297
[46]   Innate immune receptor expression in normal brain aging [J].
Letiembre, M. ;
Hao, W. ;
Liu, Y. ;
Walter, S. ;
Mihaljevic, I. ;
Rivest, S. ;
Hartmann, T. ;
Fassbender, K. .
NEUROSCIENCE, 2007, 146 (01) :248-254
[47]   Peripheral Mitochondrial Dysfunction in Alzheimer's Disease: Focus on Lymphocytes [J].
Leuner, Kristina ;
Schulz, Kathrin ;
Schuett, Tanja ;
Pantel, Johannes ;
Prvulovic, David ;
Rhein, Virginie ;
Savaskan, Egemen ;
Czech, Christian ;
Eckert, Anne ;
Mueller, Walter E. .
MOLECULAR NEUROBIOLOGY, 2012, 46 (01) :194-204
[48]   Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein [J].
Lewis, J ;
McGowan, E ;
Rockwood, J ;
Melrose, H ;
Nacharaju, P ;
Van Slegtenhorst, M ;
Gwinn-Hardy, K ;
Murphy, MP ;
Baker, M ;
Yu, X ;
Duff, K ;
Hardy, J ;
Corral, A ;
Lin, WL ;
Yen, SH ;
Dickson, DW ;
Davies, P ;
Hutton, M .
NATURE GENETICS, 2000, 25 (04) :402-405
[49]   Intranasal inoculation with an adenovirus vaccine encoding ten repeats of Aβ3-10 reduces AD-like pathology and cognitive impairment in Tg-APPswe/PSEN1dE9 mice [J].
Li, Yu ;
Ma, Ying ;
Zong, Li-Xia ;
Xing, Xiao-Na ;
Guo, Rong ;
Jiang, Tong-Zi ;
Sha, Sha ;
Liu, Li ;
Cao, Yun-Peng .
JOURNAL OF NEUROIMMUNOLOGY, 2012, 249 (1-2) :16-26
[50]  
Mallard Carina, 2012, ISRN Neurol, V2012, P701950, DOI 10.5402/2012/701950
123456789